Prostatype Genomics AB (PROGEN) — Cash Flow-to-Debt Ratio
Prostatype Genomics AB (PROGEN) has a Cash Flow-to-Debt Ratio of -1.16x as of June 2025, meaning its operating cash flow of Skr-8.54 Million could theoretically repay -1% of its total liabilities (Skr7.36 Million) in one year. See Prostatype Genomics AB (PROGEN) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Prostatype Genomics AB Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Prostatype Genomics AB across 8 annual periods. Also explore Prostatype Genomics AB net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Prostatype Genomics AB (2016–2024)
Year-by-year debt coverage analysis for Prostatype Genomics AB. For market capitalisation and broader financial context, see Prostatype Genomics AB market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -5.26x | Skr-44.71 Million | Skr8.50 Million | ▼ -343.1% |
| 2023 | -1.19x | Skr-29.14 Million | Skr24.55 Million | ▲ +79.4% |
| 2022 | -5.77x | Skr-27.69 Million | Skr4.80 Million | ▼ -54.2% |
| 2021 | -3.74x | Skr-16.08 Million | Skr4.30 Million | ▼ -36.6% |
| 2020 | -2.74x | Skr-14.71 Million | Skr5.37 Million | ▼ -156.7% |
| 2018 | -1.07x | Skr-9.63 Million | Skr9.03 Million | ▼ -152.0% |
| 2017 | -0.42x | Skr-5.71 Million | Skr13.49 Million | ▲ +79.0% |
| 2016 | -2.01x | Skr-9.63 Million | Skr4.79 Million | — |